PLUS THERAPEUTICS, Inc. Common Stock (PSTV) is a publicly traded Healthcare sector company. As of May 19, 2026, PSTV trades at $5.96 with a market cap of $36.03M and a P/E ratio of -19.12. PSTV moved +3.85% today. Year to date, PSTV is -57.91%; over the trailing twelve months it is -44.38%. Its 52-week range spans $2.90 to $57.75. Analyst consensus is strong buy with an average price target of $38.00. Rallies surfaces PSTV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Plus Therapeutics Deploys AI Platform for CNS Oncology Data Integration Starting 2026: Plus Therapeutics signed an agreement with Ephemeral Technologies to deploy an AI-native platform integrating its therapeutic, diagnostic and bioinformatics datasets for CNS oncology. Plus expects laboratory and clinical operating improvements starting in 2026 and plans to scale AI-driven decision support, patient stratification, precision oncology and real-world evidence workflows.
| Metric | Value |
|---|---|
| Price | $5.96 |
| Market Cap | $36.03M |
| P/E Ratio | -19.12 |
| EPS | $-0.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $57.75 |
| 52-Week Low | $2.90 |
| Volume | 81.82K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.21M |
| Net Income | $-22.39M |
| Gross Margin | 0.00% |
5 analysts cover PSTV: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $38.00.